Healthcare
Sangamo Therapeutics, Inc.(SGMO)
Live Price
Offline$0.214
+1.90% today
1Y Change
-49.07%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $60.00M
- Revenue Growth
- -31.6%
- EPS Growth
- +10.2%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sangamo Therapeutics, Inc. (SGMO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $0.21 and down 49.1% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of -31.6%, EPS growth of +10.2%, a dividend yield of 0.0%. What stands out right now is revenue -31.6%, EPS +10.2%, free cash flow -44.4% with operating margin -273.1% and ROIC -566.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SGMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-31.6% vs +7.6% peer median
Operating Margin
Below sector median
-273.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 14, 2026 with an EPS surprise of -1700.0% and a revenue surprise of -95.7%.
The operating picture looks softer than before
Revenue is at -31.6% and EPS is at +10.2%, with operating margin around -273.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | -1700.0% | +0.0% | +14.3% | โ |
2026 Mar 30, 2026 | -1318.2% | -19.7% | -16.7% | -34.9% |
2025 Nov 6, 2025 | -266.7% | +2.5% | -2.5% | +7.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGMO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SGMO Max Drawdown
-86.47%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SGMO and SPY.
Company Overview
Sangamo Therapeutics, Inc.
NASDAQ Global Select
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
- Leadership
- Alexander D. Macrae Ch.B
- IPO Date
- Apr 6, 2000
- Employees
- 183
- Street Address
- 501 Canal Blvd
- Mailing
- Richmond, CA, 94005
- Region
- Richmond, CA, US
- Reporting Currency
- USD
- Investor Line
- 510 970 6000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.4
- Price/Book
- โ
Growth
- Revenue
- -31.6%
- EPS
- +10.2%
- Free Cash Flow
- -44.4%
Profitability
- Gross Margin
- 80.8%
- Operating Margin
- -273.1%
- Net Margin
- -310.8%
- ROE
- -2983.2%
- ROIC
- -566.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.84
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.